{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:46:25Z","timestamp":1782906385455,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jfma.2021.07.019","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T01:41:11Z","timestamp":1627695671000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of young adult patients with very-high-risk acute lymphoblastic leukemia treated with pediatric-type chemotherapy \u2013 a single institute experience"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-9511","authenticated-orcid":false,"given":"Chao-Neng","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-8324","authenticated-orcid":false,"given":"Sin-Syue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-8054","authenticated-orcid":false,"given":"Tsai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Shiuh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.07.019_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.07.019_bib2","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/cncr.30624","article-title":"Acute lymphoblastic leukemia in adolescents and young adults","volume":"123","author":"Rytting","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2021.07.019_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2018-02-778530","article-title":"Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?","volume":"132","author":"Boissel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2021.07.019_bib6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2021.07.019_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bjh.16242","article-title":"Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients","volume":"188","author":"Kim","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jfma.2021.07.019_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1200\/JCO.18.00822","article-title":"Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study","volume":"37","author":"Pui","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jfma.2021.07.019_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41375-019-0598-2","article-title":"T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol","volume":"34","author":"Quist-Paulsen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2021.07.019_bib12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2021.07.019_bib13","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children's Oncology group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jfma.2021.07.019_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"3","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib15","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720903531","article-title":"Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population","volume":"11","author":"Carobolante","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jfma.2021.07.019_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0b013e32833156eb","article-title":"Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia","volume":"21","author":"Mattison","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2021.07.019_bib20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib21","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2021.07.019_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/leu.2009.248","article-title":"Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia","volume":"24","author":"Liang","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2021.07.019_bib23","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of total therapy study XIIIB at St jude children's research hospital","volume":"104","author":"Pui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St jude total therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jfma.2021.07.019_bib25","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2021.07.019_bib26","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib28","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","article-title":"Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"96","author":"Coustan-Smith","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.leukres.2007.03.006","article-title":"Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia","volume":"31","author":"Chen","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.jfma.2021.07.019_bib30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jfma.2016.12.002","article-title":"Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: fusion transcripts and leukemia-associated immunophenotypes","volume":"116","author":"Huang","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2021.07.019_bib31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2021.07.019_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/asheducation-2017.1.22","article-title":"Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation","volume":"2017","author":"Ravandi","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.jfma.2021.07.019_bib34","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/pbc.26139","article-title":"Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?","volume":"63","author":"Schmiegelow","year":"2016","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.jfma.2021.07.019_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00043426-199024000-00010","article-title":"Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts?","volume":"12","author":"Schmiegelow","year":"1990","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?","volume":"21","author":"Schiffer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2021.07.019_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/08880018.2016.1276235","article-title":"Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia","volume":"34","author":"Yeoh","year":"2017","journal-title":"Pediatr Hematol Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621003508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621003508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:46:51Z","timestamp":1760539611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621003508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0929664621003508"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.07.019","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of young adult patients with very-high-risk acute lymphoblastic leukemia treated with pediatric-type chemotherapy \u2013 a single institute experience","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}